AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3544782
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment for inferior AMI with high ST-segment elevation
Trial: 3544782
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment for inferior AMI with marked contralateral ST-segment depression
Trial: 3544782
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for anterior AMI
Trial: 3544782
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for inferior AMI
Trial: 24323062
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% sodium chloride) solution
Trial: 24323062
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% sodium chloride) solution with added gentamicin (80 mg/L)
Trial: 20417857
Drug: Pyronaridine-artesunate (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyronaridine-artesunate (180 mg pyronaridine and 60 mg artesunate once a day for 3 days)
Trial: 20417857
Drug: Artemether-lumefantrine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (20 mg artemether and 120 mg lumefantrine twice a day for 3 days)
Trial: 11236340
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of piperacillin sodium (2 g i.v. after umbilical cord clamping)
Trial: 11236340
Drug: Triple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple doses of piperacillin sodium (2 g i.v. at 6 hourly intervals starting from umbilical cord clamping)
Trial: 29762764
Drug: Ethanol 0.6
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.6 g/kg
Trial: 29762764
Drug: Ethanol 0.45
RxNorm normalized name: FRAGRANCE 13576 0.15 g in 50 mL / GRAPE SEED OIL 0.25 g in 50 mL / GLYCERYL MONOSTEARATE 3.5 g in 50 mL / LINALOOL, (+/-)- 0.0114 g in 50 mL / PHENOXYETHANOL 0.45 g in 50 mL / PROPYLENE GLYCOL 1.5 g in 50 mL / TITANIUM DIOXIDE 0.25 g in 50 mL / PALMITIC ACID 1 g in 50 mL / BUTYLATED HYDROXYTOLUENE 0.25 g in 50 mL / STARCH, RICE 5.5 g in 50 mL / ALCOHOL 4.752 mL in 50 mL / C12-20 ACID PEG-8 ESTER 1 g in 50 mL / TROLAMINE 0.25 g in 50 mL / ISOMETHYL-.ALPHA.-IONONE 0.00639 g in 50 mL / HYDROXYACETOPHENONE 0.25 g in 50 mL / PERLITE 4 g in 50 mL / GLYCERIN 0.0115 g in 50 mL / ETHYLHEXYLGLYCERIN 0.05 g in 50 mL / .BETA.-CITRONELLOL, (R)- 0.012 g in 50 mL / WATER 25.04945 g in 50 mL / STEARIC ACID 1 g in 50 mL / CETEARYL ETHYLHEXANOATE 0.75 g in 50 mL TOPICAL CREAM [Anubis Barcelona Spa Line]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.45 g/kg
Trial: 27395380
Drug: Amitriptyline 50
RxNorm normalized name: amitriptyline 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 50 mg/d (25 mg twice daily)
Trial: 22700528
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (IIT) for 24 hours
Trial: 22700528
Drug: Usual subcutaneous
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual subcutaneous insulin for 24 hours
Trial: 22700528
Drug: Usual subcutaneous
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual subcutaneous insulin
Trial: 19776507
Drug: 0.18% isotretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.18% isotretinoin applied topically twice a day for one month
Trial: 11512369
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg.kg‐1)
Trial: 11512369
Drug: Thiopental (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (5 mg.kg‐1)
Trial: 7851104
Drug: Supported employment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supported employment program (changed from day treatment)
Trial: 7851104
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment program (control)
Trial: 29793566
Drug: Resin infiltration
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin infiltration followed by five percent topical sodium fluoride (NaF) application
Trial: 24630840
Drug: Tribulus terrestris
RxNorm normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribulus terrestris 800 mg, divided into two doses per day for thirty days
Trial: 24630840
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in the same way as the intervention
Trial: 12207107
Drug: Non-treatment-resistant depression
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment-resistant depression (non-TRD)
Trial: 7053283
Drug: Sulfinpyrazone, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfinpyrazone, 400 mg daily
Trial: 7053283
Drug: S-warfarin with
RxNorm normalized name: (S)-Warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-warfarin with sulfinpyrazone
Trial: 7053283
Drug: R-warfarin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-warfarin with sulfinpyrazone
Trial: 27513640
Drug: Epidural 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural 0.125% ropivacaine with dexmedetomidine (0.5 μg/kg)
Trial: 21336156
Drug: Quadruple sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple sequential therapy plus 6 weeks of iron supplementation
Trial: 21336156
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy plus placebo
Trial: 15998749
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g of isolated soybean protein supplements per day
Trial: 6343154
Drug: Intravenous maprotiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous maprotiline (100 mg daily)
Trial: 6343154
Drug: Intravenous clomipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clomipramine (Anafranil)
Trial: 31955859
Drug: Lenvatinib 24
RxNorm normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 24 mg once daily in a 28-day dosing cycle
Trial: 31618331
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between PAR-G and 1PO-G
Trial: 23937679
Drug: Epelsiban 50
RxNorm normalized name: Epelsiban
DrugBank: Epelsiban (DB11934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epelsiban 50 mg
Trial: 23937679
Drug: Epelsiban 150
RxNorm normalized name: Epelsiban
DrugBank: Epelsiban (DB11934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epelsiban 150 mg
Trial: 17572830
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg, 1 hour before bedtime)
Trial: 17012882
Drug: DTaP‐IPV//PRP‐T combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP‐IPV//PRP‐T combination vaccine (Pentacel) administered as a fourth dose at 15, 16, 17, or 18 months of age.
Trial: 17012882
Drug: DTaP‐IPV//PRP‐T combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP‐IPV//PRP‐T combination vaccine (Pentacel) administered as a fourth dose.
Trial: 12459073
Drug: pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 10 mg
Trial: 10588407
Drug: ABT-418 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-418 (75 mg/day)
Trial: 24549101
Drug: RG3487 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG3487 5 mg
Trial: 24549101
Drug: RG3487 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG3487 50 mg
Trial: 24549101
Drug: RG3487 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG3487 15 mg
Trial: 22242614
Drug: Preoperative total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative total parenteral nutrition (TPN) for 18‐90 days (mean, 46 days)
Trial: 16174587
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid injection into the amniotic cavity
Trial: 16174587
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of compound amino acid
Trial: 12037731
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of glucose
Trial: 9638715
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of mannitol
Trial: 12037731
Drug: insulin‐induced hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: insulin‐induced hypoglycemia
Trial: 10221717
Drug: Relaxin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxin administration (up to 10 times higher than during pregnancy)
Trial: 10221717
Drug: Relaxin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxin administration
Trial: 345342
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg glucagon
Trial: 29295829
Drug: Medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication therapy management intervention (single home visit by a pharmacist within 7 days of discharge)
Trial: 29295829
Drug: Medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication therapy management intervention
Trial: 27720040
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (high dose)
Trial: 27720040
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (low dose)
Trial: 12826992
Drug: Mirtazapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15 mg/day)
Trial: 10403850
Drug: Neostigmine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (2.0 mg intravenously)
Trial: 8899087
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 1000 mg plus vitamin D 250 IU (Oscal)
Trial: 1647337
Drug: Pyridostigmine, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine, 30 mg three times daily for 10 days
Trial: 1647337
Drug: Placebo, similar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, similar dosage and duration as treatment group
Trial: 31335802
Drug: Oral tenofovir‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tenofovir‐based pre‐exposure prophylaxis (PrEP)
Trial: 30037068
Drug: Resveratrol (RSV)
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (RSV) 500 mg/day
Trial: 27372432
Drug: Selective COX-2
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective COX-2 inhibitor etoricoxib
Trial: 23390784
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection of 20 ml 0.25% bupivacaine
Trial: 23390784
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution (control)
Trial: 15915026
Drug: Active nicotine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active nicotine-containing patches
Trial: 9252901
Drug: 13C-xylose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13C-xylose (50 mg)
Trial: 9252901
Drug: Control groups
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control groups (10 mg and 25 mg 13C-xylose)
Trial: 8391042
Drug: Lymphoblastoid interferon
RxNorm normalized name: interferon alfa-n1 lymphoblastoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphoblastoid interferon (administered in a step-down schedule for 12 months)
Trial: 3505532
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg oral administration)
Trial: 29335043
Drug: Endoscopic repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic repair using a mirrored L‐shaped flap without stenting (Group A)
Trial: 28410809
Drug: Radiotherapy 60Gy/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy 60Gy/30 fractions with oral vinorelbine 50mg 3 times weekly
Trial: 28410809
Drug: Radiotherapy 66Gy/33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy 66Gy/33 fractions with oral vinorelbine 50mg 3 times weekly
Trial: 26154736
Drug: Posterior subtenon's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior subtenon's injection of 40 mg of triamcinolone acetonide
Trial: 26154736
Drug: Grid laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grid laser photocoagulation (GLP) combined with posterior subtenon's triamcinolone injection
Trial: 23496861
Drug: Nicotine e-cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine e-cigarettes (16 mg)
Trial: 21680726
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control therapy (IT) for 2 weeks
Trial: 15012688
Drug: Low GDP
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low GDP solution (pH 7.0)
Trial: 15012688
Drug: High GDP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High GDP solution (pH 5.5)
Trial: 9085977
Drug: BIS-guided group
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS-guided group (anesthetic drug doses increased to produce a lower BIS)
Trial: 8441793
Drug: SAMe 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAMe 1,600 mg/day
Trial: 31080092
Drug: Telephone peer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone peer coaching (weekly 30-min calls for 6 months)
Trial: 16275243
Drug: Oxiplex/AP Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiplex/AP Gel
Trial: 9857882
Drug: Sarpogrelate 200
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate 200 mg orally administered
Trial: 2228077
Drug: Indomethacin suppositories
RxNorm normalized name: Indomethacin Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppositories (100 mg 1‐3 times a day)
Trial: 26375
Drug: Pilocarpine 4%
RxNorm normalized name: PILOCARPINE 4% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine 4% solution at pH 4.1
Trial: 26375
Drug: Pilocarpine 4%
RxNorm normalized name: PILOCARPINE 4% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine 4% solution at pH 5.8
Trial: 15168040
Drug: High intake
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intake diet (810 g/10 MJ of vegetables, berries, and apple)
Trial: 15168040
Drug: Low intake
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intake diet (196 g/10 MJ of vegetables, berries, and apple)
Trial: 11248360
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (300 mg twice daily for 3 months)
Trial: 9676168
Drug: PTCA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTCA plus heparin-coated stent (n = 202)
Trial: 2573301
Drug: Systemically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemically administered terfenadine
Trial: 2573301
Drug: Systemically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemically administered cetirizine
Trial: 29247107
Drug: Low-dose prednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisolone (0.5 mg/kg daily) plus rituximab (375 mg/m2 weekly)
Trial: 29247107
Drug: High-dose prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisolone (1 mg/kg daily) plus rituximab
Trial: 26011742
Drug: Crushed ALO-02
RxNorm normalized name: miconazole nitrate 0.02 MG/MG [Aloe Vesta Antifungal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed ALO-02 (30 mg oxycodone/3.6 mg naltrexone)
Trial: 26011742
Drug: Oxycodone immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone immediate-release (IR) (30 mg)
Trial: 10360713
Drug: Monthly measurement
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly measurement of access flow (QAT)
Trial: 10360713
Drug: Monthly measurement
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly measurement of static venous pressure (VPS)
Trial: 10360713
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no monthly monitoring)
Trial: 2008802
Drug: Vaccine A
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine A (oral, 3 doses at 14-day intervals)
Trial: 2008802
Drug: Vaccine B
RxNorm normalized name: meningococcal vaccine B and C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine B (oral, 3 doses at 14-day intervals)
Trial: 2008802
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 ml 5% NaHCO3, oral, 3 doses at 14-day intervals)
Trial: 29580634
Drug: D-Cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-Cycloserine (DCS) 100 mg
Trial: 28832388
Drug: Non‐op treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐op treatment
Trial: 28832388
Drug: OP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OP treatment with hook plate fixation
Trial: 25823991
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g Fibersol-2
Trial: 25823991
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g Fibersol-2 (Control)
Trial: 25823991
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g Fibersol-2
Trial: 15036674
Drug: Neoadjuvant cisplatinum
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant cisplatinum based combination chemotherapy (with adriamycin or methotrexate)
Trial: 9612112
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment of factor XIII twice daily for ten days (treatment group, n = 16)
Trial: 7838916
Drug: R10 min/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R10 min/3 mg
Trial: 7838916
Drug: R1h/5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R1h/5 mg
Trial: 7838916
Drug: R4h/9 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R4h/9 mg
Trial: 3377148
Drug: Nalbuphine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.05 mg/kg combined with midazolam 0.05 mg/kg
Trial: 3377148
Drug: Nalbuphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.1 mg/kg combined with midazolam 0.05 mg/kg
Trial: 3377148
Drug: Nalbuphine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.2 mg/kg combined with midazolam 0.05 mg/kg
Trial: 3377148
Drug: Nalbuphine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.05 mg/kg
Trial: 26174719
Drug: Pharmacogenetic arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic arm (200 mg of atazanavir twice daily for patients with unfavourable genotypes)
Trial: 26174719
Drug: Standard-dose arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose arm (400 mg of atazanavir once daily)
Trial: 20840347
Drug: synchronous balneophototherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: synchronous balneophototherapy (sBPT) consisting of narrowband UVB PT with 311 nm and synchronous bathing in 10% Dead Sea salt solution
Trial: 19819665
Drug: SC morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC morphine plus rHuPH20 (150U)
Trial: 19819665
Drug: SC morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC morphine plus placebo (normal saline)
Trial: 16723653
Drug: Implant Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant Group (n = 62)
Trial: 15622663
Drug: Parecoxib 20
RxNorm normalized name: parecoxib 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib 20 mg i.m.
Trial: 1931399
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg i.m.